U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H30O2
Molecular Weight 314.4625
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DRONABINOL

SMILES

CCCCCc1cc(c2[C@]3([H])C=C(C)CC[C@@]3([H])C(C)(C)Oc2c1)O

InChI

InChIKey=CYQFCXCEBYINGO-IAGOWNOFSA-N
InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1

HIDE SMILES / InChI

Molecular Formula C21H30O2
Molecular Weight 314.4625
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including http://www.who.int/medicines/areas/quality_safety/4.2DronabinolCritReview.pdf

Dronabinol also known as (−)-trans-delta9-tetrahydrocannabinol is an active ingredient of cannabis. The drug was approved by FDA for the treatment of anorexia in patients with AIDS and chemotherapy-induced nausea and vomiting. Dronabinol exerts its action by activating CB1 and CB2 recepors which makes it a CNS active medicine.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P34972
Gene ID: 1269
Gene Symbol: CNR2
Target Organism: Homo sapiens (Human)
3.12999999999999989 nM [Ki]
Target ID: P21554|||Q5UB37
Gene ID: 1268
Gene Symbol: CNR1
Target Organism: Homo sapiens (Human)
5.04999999999999982 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MARINOL

Approved Use

MARINOL Capsules is indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Launch Date

486345600000
Secondary
MARINOL

Approved Use

MARINOL Capsules is indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Launch Date

486345600000
Secondary
MARINOL

Approved Use

MARINOL Capsules is indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Launch Date

486345600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.88 ng/mL
10 mg 2 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
1.32 ng/mL
2.5 mg 2 times / day multiple, oral
dose: 2.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2.96 ng/mL
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
15.2 ng × h/mL
10 mg 2 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2.88 ng × h/mL
2.5 mg 2 times / day multiple, oral
dose: 2.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
6.16 ng × h/mL
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
10 mg 2 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
3%
2.5 mg 2 times / day multiple, oral
dose: 2.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
3%
5 mg 2 times / day multiple, oral
dose: 5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DRONABINOL unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Other AEs: Palpitations, Tachycardia...
Other AEs:
Palpitations (2.5%)
Tachycardia (2.5%)
Photophobia (2.5%)
Vision blurred (2.5%)
Eye irritation (2.5%)
Dry mouth (40%)
Fatigue (30%)
Feeling of relaxation (5%)
Hunger (10%)
Feeling hot (5%)
Thirst (5%)
Chills (2.5%)
Upper respiratory tract infection (2.5%)
Hordeolum (2.5%)
Increased appetite (7.5%)
Polydipsia (2.5%)
Sensation of heaviness (2.5%)
Muscle spasms (2.5%)
Somnolence (37.5%)
Headache (10%)
Dizziness (5%)
Paraesthesia (2.5%)
Dysgeusia (5%)
Hypoaesthesia (2.5%)
Hypotonia (2.5%)
Sources:
2.5 mg 2 times / day multiple, oral
Dose: 2.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Headache...
Other AEs:
Headache (below serious, 3 patients)
Sources:
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Diabetes, Concussion...
Other AEs:
Diabetes (serious, 1 patient)
Concussion (serious, 1 patient)
Nausea (below serious, 5 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache 10%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Hunger 10%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Chills 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Eye irritation 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Hordeolum 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Hypoaesthesia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Hypotonia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Muscle spasms 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Palpitations 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Paraesthesia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Photophobia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Polydipsia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Sensation of heaviness 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Tachycardia 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Upper respiratory tract infection 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Vision blurred 2.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Fatigue 30%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Somnolence 37.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Dry mouth 40%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Dizziness 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Dysgeusia 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Feeling hot 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Feeling of relaxation 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Thirst 5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Increased appetite 7.5%
30 mg 1 times / day single, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
unhealthy, mean age 36 years
Health Status: unhealthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Headache below serious, 3 patients
2.5 mg 2 times / day multiple, oral
Dose: 2.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nausea below serious, 5 patients
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Concussion serious, 1 patient
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diabetes serious, 1 patient
20 mg 2 times / day multiple, oral
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes (pharmacogenomic study)
Comment: Published data indicate a 2- to 3-fold higher dronabinol exposure in individuals carrying genetic variants associated with diminished CYP2C9 function
Page: 13
PubMed

PubMed

TitleDatePubMed
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.
1999 May 11
Case report: adverse effects of taking tricyclic antidepressants and smoking marijuana.
1999 Nov
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain.
2000 Dec
Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice.
2001 Feb
Differential role of the nitric oxide pathway on delta(9)-THC-induced central nervous system effects in the mouse.
2001 Feb
Behavioral suppression induced by cannabinoids is due to activation of the arachidonic acid cascade in rats.
2001 Jan 19
The pharmacological activity of inhalation exposure to marijuana smoke in mice.
2001 Jul 1
SPME-GC analysis of THC in saliva samples collected with "EPITOPE" device.
2001 Jul 15
Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates.
2001 Jun
Effects of fluvoxamine on ethanol-reinforced behavior in the rat.
2001 Jun
Cannabinoidergic and opioidergic inhibition of spinal reflexes in the decerebrated, spinalized rabbit.
2001 Mar
The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.
2001 May
Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia.
2001 May 18
Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
2001 May-Jun
Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
2001 May-Jun
Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.
2001 Oct
Solid-phase extraction and GC-MS analysis of THC-COOH method optimized for a high-throughput forensic drug-testing laboratory.
2001 Oct
The psychoactive ingredient of marijuana induces behavioural sensitization.
2001 Sep
Identification and quantitation of 11-nor-delta9-tetrahydrocannabivarin-9-carboxylic acid, a major metabolite of delta9-tetrahydrocannabivarin.
2001 Sep
Role of gonadal steroids in the corticotropin-releasing hormone and proopiomelanocortin gene expression response to Delta(9)-tetrahydrocannabinol in the hypothalamus of the rat.
2001 Sep
R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism.
2001 Sep 7
Patents

Sample Use Guides

Appetite Stimulation: Initially, 2.5 mg capsules should be administered orally twice daily, before lunch and supper. For patients unable to tolerate this 5 mg/day dosage, the dosage can be reduced to 2.5 mg/day, administered as a single dose in the evening or at bedtime. Antiemetic: it is best administered at an initial dose of 5 mg/m2, given 1 to 3 hours prior to the administration of chemotherapy, then every 2 to 4 hours after chemotherapy is given, for a total of 4 to 6 doses/day. Should the 5 mg/m2 dose prove to be ineffective, and in the absence of significant side effects, the dose may be escalated by 2.5 mg/m2 increments to a maximum of 15 mg/m2 per dose.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:36:53 UTC 2021
Edited
by admin
on Fri Jun 25 20:36:53 UTC 2021
Record UNII
7J8897W37S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DRONABINOL
HSDB   INN   MART.   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
INN   USAN  
Official Name English
.DELTA.1-THC
Common Name English
MARINOL
Brand Name English
QCD 84924
Code English
ABBOTT 40566
Code English
THC
Common Name English
SP 104
Code English
TETRAHYDROCANNABINOLS (-)-TRANS-.DELTA.9-FORM
MI  
Common Name English
TETRAHYDROCANNABINOL
Common Name English
(6AR,10AR)-6,6,9-TRIMETHYL-3-PENTYL-6A,7,8,10A-TETRAHYDRO-6H-DIBENZO(B,D)PYRAN-1-OL
Common Name English
DELTA-9-TETRAHYDROCANNABINOL
Common Name English
DELTA-9-THC
Common Name English
(6AR,10AR)-6A,7,8,10A-TETRAHYDRO-6,6,9-TRIMETHYL-3-PENTYL-6H-DIBENZO(B,D)PYRAN-1-OL
Common Name English
ABBOTT-40566
Code English
DRONABINOL [ORANGE BOOK]
Common Name English
J882F
Code English
.DELTA.9-THC
Common Name English
QCD-84924
Code English
DRONABINOL [VANDF]
Common Name English
DRONABINOL [INN]
Common Name English
TETRAHYDROCANNABINOL, DELTA-9 TRANS
Common Name English
SP-104
Code English
.DELTA.-9-TETRAHYDROCANNABINOL
Common Name English
6H-DIBENZO(B,D)PYRAN-1-OL, 6A,7,8,10A-TETRAHYDRO-6,6,9-TRIMETHYL-3-PENTYL-, (6AR,10AR)-
Common Name English
DELTA-9-TETRAHYDROCANNABINOL (CANNABIS SATIVA EXTRACT)
Common Name English
.DELTA.9-TETRAHYDROCANNABINOL
Common Name English
DRONABINOL [USAN]
Common Name English
(-)-.DELTA.1-3,4-TRANS-TETRAHYDROCANNABINOL
Common Name English
DRONABINOL [WHO-DD]
Common Name English
DRONABINOL [HSDB]
Common Name English
DRONABINOL [MART.]
Common Name English
DRONABINOL [USP MONOGRAPH]
Common Name English
NSC-134454
Code English
TETRAHYDROCANNABINOLS (-)-TRANS-.DELTA.9-FORM [MI]
Common Name English
6H-DIBENZO(B,D)PYRAN-1-OL, 6A,7,8,10A-TETRAHYDRO-6,6,9-TRIMETHYL-3-PENTYL-, (6AR-TRANS)-
Common Name English
Classification Tree Code System Code
NDF-RT N0000008010
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 668918
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
DEA NO. 7369
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
NCI_THESAURUS C267
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
LIVERTOX 947
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
WHO-ATC A04AD10
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 498215
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
CFR 21 CFR 1308.35
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 652218
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 54890
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
EU-Orphan Drug EU/3/16/1621
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
WHO-ATC N02BG10
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
NDF-RT N0000175782
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 628818
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
WHO-VATC QA04AD10
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 620417
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 549616
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
FDA ORPHAN DRUG 734820
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL465
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
RXCUI
10402
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
4109
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
IUPHAR
2424
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
INN
5547
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
EVMPD
SUB06407MIG
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
DRUG BANK
DB00470
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
EPA CompTox
1972-08-3
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
MERCK INDEX
M10624
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
TETRAHYDROCANNABINOL
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
LACTMED
Dronabinol
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
FDA UNII
7J8897W37S
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
MESH
D013759
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
NCI_THESAURUS
C867
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
PUBCHEM
16078
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
CAS
1972-08-3
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
HSDB
6471
Created by admin on Fri Jun 25 20:36:53 UTC 2021 , Edited by admin on Fri Jun 25 20:36:53 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
MINOR
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
METABOLIC ENZYME -> SUBSTRATE
MINOR
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT
Delta-9-tetrahydrocannabinol class | Euphoriant | Analgesic | Anti-inflammatory | Antioxidant | Antiemetic
TARGET -> AGONIST
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE ACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
URINE
METABOLITE -> PARENT
IN VITRO
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY